APA (7th ed.) Citation

PG, R., SJ, H., S, B., F, S., K, Y., F, C., . . . MA, D. (2021). Isatuximab for relapsed/refractory multiple myeloma: Review of key subgroup analyses from the Phase III ICARIA-MM study. Future oncology (London, England), 17(34), 4797. https://doi.org/10.2217/fon-2021-0568

Chicago Style (17th ed.) Citation

PG, Richardson, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, Le-Guennec S, Macé S, and Dimopoulos MA. "Isatuximab for Relapsed/refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study." Future Oncology (London, England) 17, no. 34 (2021): 4797. https://doi.org/10.2217/fon-2021-0568.

MLA (9th ed.) Citation

PG, Richardson, et al. "Isatuximab for Relapsed/refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study." Future Oncology (London, England), vol. 17, no. 34, 2021, p. 4797, https://doi.org/10.2217/fon-2021-0568.